DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for alopecia — screening already-approved drugs against its 31-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAlopecia maps to a 31-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for alopecia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nudix hydrolase 15 (NUDT15) — NUDT15 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7B67 · 1.45 Å · ligand (R)-6-((2-methyl-4-(1-methyl-1H-indole-5-carbonyl)piperazin-1-yl)sulfonyl)benzo[d]oxazol-2(3H)-one (SYW). Experimental structure, not a prediction.
What the evidence adds up to
Many therapeutic modalities have been used to treat alopecia areata, with variable efficacy and safety profiles, but none is curative or preventive. Many of these agents have not been subjected to randomised controlled trials, and except for topical immunotherapy there are few published studies on long-term outcomes. The reported efficacy of various treatments is difficult to compare because case reports, case series, and clinical trials generally fail to account for spontaneous regrowth or baseline prognostic factors in alopecia areata, and lack quantification of hair growth. Guidelines for clinical trial design have been proposed that would take into account baseline severity, pattern, and duration of hair loss, age, and concomitant conditions, alongside reliable methods of assessment to enable direct comparison between agents.
In male androgenetic alopecia, a 2017 monocentric study using scalp vertex biopsies from bald men and healthy volunteers found that genes encoding mast cell granule enzymes, inflammatory mediators, and immunoglobulin-associated immune mediators were significantly overexpressed. Underexpressed genes were associated with the Wnt/β-catenin and bone morphogenic protein/transforming growth factor-β signalling pathways. The study also reported lower expression of CYP27B1 in patients, supporting a role for changes in vitamin D metabolism in hair loss. A 2025 review of alopecia areata states that its pathogenesis remains poorly understood, driven by interactions among immune dysregulation, genetic predisposition, and environmental triggers, and that substantial gaps persist in understanding the full spectrum of molecular mechanisms and in developing effective therapeutic approaches.
Extracellular vesicles have emerged as a promising therapeutic strategy for alopecia, according to a 2025 review. Compared to traditional medications or stem cell therapies, they offer advantages including high biological safety, sustained efficacy, low risk of immune rejection, and ease of storage and transport. However, challenges such as mass production and clinical application persist, and further research is needed to optimise dosing, cell sources, and administration frequency. The review concludes that with continued innovation in manufacturing technologies and collaboration between academia and industry, extracellular vesicles hold potential for advancing clinical treatments.
What is still missing are adequately powered randomised controlled trials that account for spontaneous regrowth and baseline prognostic factors, reliable and standardised methods for quantifying hair growth, a full understanding of the molecular mechanisms driving both alopecia areata and androgenetic alopecia, and optimised protocols for the production and clinical application of extracellular vesicles, including determination of dosing, cell sources, and administration frequency.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Cosmetic and Investigational Dermatology · 2011 · 100 citations · open access
Alopecia areata: a new treatment plan
AbstractMany therapeutic modalities have been used to treat alopecia areata, with variable efficacy and safety profiles. Unfortunately, none of these agents is curative or preventive. Also, many of these therapeutic agents have not been subjected to randomized, controlled trials, and, except for topical immunotherapy, there are few published studies on long-term outcomes. The treatment plan is designed according to the patient's age and extent of disease. In this paper, the therapeutic agents are organized according to their efficacy and safety profiles into first-line, second-line, and third-line options.
AbstractThe reported efficacy of various treatments for alopecia is difficult to compare based on a general lack of consideration in case reports/series and clinical trials of the spontaneous regrowth or baseline prognostic factors seen in alopecia areata and a general lack of quantification of hair growth. This report will give both the investigator and clinician guidelines for clinical trial design that will take into account variables known to effect efficacy results such as baseline severity, pattern, and duration of hair loss, age of the subject, and concomitant conditions that may impact on potential regrowth. Reliable methods of assessment of efficacy and response criteria that will enable direct comparison of results between agents will also be discussed.
British Journal of Dermatology · 2017 · 72 citations · open access
Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signalling pathways
AbstractBACKGROUND: Male androgenetic alopecia (AGA) is the most common form of hair loss in men. It is characterized by a distinct pattern of progressive hair loss starting from the frontal area and the vertex of the scalp. Although several genetic risk loci have been identified, relevant genes for AGA remain to be defined. OBJECTIVES: To identify biomarkers associated with AGA. METHODS: Molecular biomarkers associated with premature AGA were identified through gene expression analysis using cDNA generated from scalp vertex biopsies of hairless or bald men with premature AGA, and healthy volunteers. RESULTS: This monocentric study reveals that genes encoding mast cell granule enzymes, inflammatory mediators and immunoglobulin-associated immune mediators were significantly overexpressed in AGA. In contrast, underexpressed genes appear to be associated with the Wnt/β-catenin and bone morphogenic protein/transforming growth factor-β signalling pathways. Although involvement of these pathways in hair follicle regeneration is well described, functional interpretation of the transcriptomic data highlights different events that account for their inhibition. In particular, one of these events depends on the dysregulated expression of proopiomelanocortin, as confirmed by polymerase chain reaction and immunohistochemistry. In addition, lower expression of CYP27B1 in patients with AGA supports the notion that changes in vitamin D metabolism contributes to hair loss. CONCLUSIONS: This study provides compelling evidence for distinct molecular events contributing to alopecia that may pave the way for new therapeutic approaches.
Alopecia Areata: Pathogenesis, Diagnosis, and Therapies
AbstractAlopecia areata (AA) is a complex, chronic inflammatory skin disorder characterized by unpredictable, nonscarring hair loss, affecting millions worldwide. Its pathogenesis remains poorly understood, driven by intricate interactions among immune dysregulation, genetic predisposition, and environmental triggers. Despite significant advances in identifying these contributing factors, substantial gaps persist in our understanding of the full spectrum of AA's molecular mechanisms and in the development of effective therapeutic approaches. This review aims to comprehensively explore the immunological, genetic, epigenetic, and environmental factors underlying AA, with a focus on immune-mediated mechanisms. We also evaluate diagnostic approaches and recent advancements in assessing disease severity. Furthermore, the review discusses evolving therapeutic options, including traditional therapies, biologics, small-molecule agents, and emerging treatments. The academic value of this work lies in its synthesis of current knowledge on the multifaceted nature of AA, providing insights for future research and clinical practice. By elucidating the interconnected factors underlying AA, this review seeks to advance both understanding and management of this prevalent, clinically challenging disorder.
AbstractOBJECTIVE: To determine whether there are effective treatments for postpartum alopecia. DATA SOURCES: Clinical literature identified through MEDLINE (January 1966-May 2000), EMBASE (June 1980-March 2000), and International Pharmaceutical Abstracts (January 1970-March 2000). Key search terms included alopecia, puerperium, and postpartum. DATA SYNTHESIS: Postpartum alopecia is a diffuse shedding of scalp hair that can begin two to five months following parturition. Few articles examine the treatment of this condition. Treatments in the form of thyroid supplementation, topical progesterone and estradiol lotions, and an oral contraceptive have been studied. All available studies on this subject have significant limitations, such as small sample size, absence of a control group, or subjective measurement of treatment response. Nondrug therapy for a related type of hair loss has been recommended and includes education about hair cycles and reassurance to minimize anxiety. CONCLUSIONS: From the available studies, no specific treatment has been studied well enough with sufficient treatment justify recommendation or to be termed effective.
Annals of Medicine · 2025 · 8 citations · open access
Advances in the extracellular vesicles treatment of alopecia
AbstractBACKGROUND: Alopecia is a prevalent condition that significantly impacts appearance, mental health, and overall quality of life. Current clinical treatments for alopecia include medication, hair transplantation, low-level light therapy, and stem cell therapy, among others. However, the effectiveness of these treatments remains far from ideal. Extracellular vesicles (EVs) have emerged as a promising therapeutic strategy, yet challenges, such as mass production and clinical application persist. This review aims to explore recent advancements in the use of EVs for the treatment of alopecia. METHODS: A comprehensive literature search was conducted in the PubMed database using a range of relevant keywords: extracellular vesicles, alopecia, hair loss, preparation, exosomes, microvesicles, apoptotic bodies, nanoscale particles, preclinical studies, clinical trial, clinical transformation, regenerative medicine, tissue engineering, stem cell, bioactive molecules, and extraction methods. The papers mostly focus on the biological characteristics and preparation of EVs, the basic and clinical research of EVs in the treatment of hair loss, and the challenges of clinical transformation of EVs were retracted. RESULTS: membrane fusion or endocytosis. Compared to traditional medications or stem cell therapies, EVs offer several advantages, including high biological safety, sustained efficacy, low risk of immune rejection, and ease of storage and transportation. These properties make them a highly promising therapeutic option. CONCLUSION: Significant progress has been made in understanding the preparation, mechanisms, and early clinical applications of EVs. However, further research is needed to optimize key factors, such as dosing, cell sources, and administration frequency to develop more effective and safer therapies. With continued innovation in manufacturing technologies and collaborative efforts between academia and industry, EVs hold great potential for advancing clinical treatments for alopecia in the future.
AbstractThere are a number of options available for the medical management of androgenetic alopecia. The key questions for practitioners are what the available medications are and what is their efficacy? What are the possible side-effects of these options? Are there differences in response according to parameters like gender? Are combinations effective? What are the newer options available and what could the future hold? This narrative review attempts to answer these questions. The main focus is on the medical treatment options which have significant evidence as of now – minoxidil, 5 alfa-reductase inhibitors, low light laser therapy, and platelet-rich plasma.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
